Literature DB >> 11318427

Simultaneous determination of quinine and four metabolites in plasma and urine by high-performance liquid chromatography.

R A Mirghani1, O Ericsson, J Cook, P Yu, L L Gustafsson.   

Abstract

The determination of quinine, (3S)-3-hydroxyquinine, 2'-quininone and (10R)- and (10S)-10,11-dihydroxydihydroquinine in plasma and urine samples is described. This is the first time the R and S configurations have been correctly assigned to the two metabolites of 10,11-dihydroxyquinine. One hundred microliter-plasma samples were protein precipitated with 200 microl cold methanol. Urine samples were 10-100 x diluted and then directly injected into the HPLC. A reversed-phase liquid chromatography system with fluorescence detection and a Zorbax Eclipse XDB phenyl column and gradient elution was used. The within and between assay coefficients of variation of the method for quinine and its metabolites in plasma and urine was less than 13%. The lower limit of quantitation was in the range of 0.024-0.081 microM.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11318427     DOI: 10.1016/s0378-4347(00)00577-6

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  9 in total

1.  Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration.

Authors:  Julius O Soyinka; Cyprian O Onyeji; Sharon I Omoruyi; Adegbenga R Owolabi; Pullela V Sarma; James M Cook
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

2.  Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers.

Authors:  Annika Allqvist; Jun Miura; Leif Bertilsson; Rajaa A Mirghani
Journal:  Eur J Clin Pharmacol       Date:  2007-01-03       Impact factor: 2.953

3.  Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients.

Authors:  Anna Svedberg; Svante Vikingsson; Anders Vikström; Niels Hornstra; Magnus Kentson; Eva Branden; Hirsh Koyi; Bengt Bergman; Henrik Gréen
Journal:  Br J Clin Pharmacol       Date:  2019-05-27       Impact factor: 4.335

4.  Effects of Plasmodium falciparum infection on the pharmacokinetics of quinine and its metabolites in pregnant and non-pregnant Sudanese women.

Authors:  Rajaa A Mirghani; Ishraga Elagib; Gehad Elghazali; Urban Hellgren; Lars L Gustafsson
Journal:  Eur J Clin Pharmacol       Date:  2010-08-18       Impact factor: 2.953

5.  Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers.

Authors:  Julius O Soyinka; Cyprian O Onyeji; Sharon I Omoruyi; Adegbenga R Owolabi; Pullela V Sarma; James M Cook
Journal:  J Pharm Pharmacol       Date:  2009-04       Impact factor: 3.765

6.  CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity.

Authors:  Henrik Gréen; Karin Skoglund; Franz Rommel; Rajaa A Mirghani; Kourosh Lotfi
Journal:  Eur J Clin Pharmacol       Date:  2010-04       Impact factor: 2.953

7.  Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man.

Authors:  Rajaa A Mirghani; Orjan Ericsson; Gunnel Tybring; Lars L Gustafsson; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2003-03-11       Impact factor: 2.953

8.  Metabolism and elimination of quinine in healthy volunteers.

Authors:  Rajaa A Mirghani; Urban Hellgren; Leif Bertilsson; Lars L Gustafsson; Orjan Ericsson
Journal:  Eur J Clin Pharmacol       Date:  2003-08-12       Impact factor: 2.953

9.  Population pharmacokinetic and pharmacodynamic properties of intramuscular quinine in Tanzanian children with severe Falciparum malaria.

Authors:  Ilse C E Hendriksen; Deogratius Maiga; Martha M Lemnge; George Mtove; Samwel Gesase; Hugh Reyburn; Niklas Lindegardh; Nicholas P J Day; Lorenz von Seidlein; Arjen M Dondorp; Joel Tarning; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2012-11-26       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.